Zydus Lifesciences has delayed the acquisition of Sterling Biotech's API business to September 30, 2026, as the seller works to fulfill pending agreement conditions. Separately, the company is addressing a USFDA warning letter for its Baddi plant, though it expects no impact on current operations.
What Happened
Zydus Lifesciences has pushed the closing date for its acquisition of the Active Pharmaceutical Ingredient (API) business from Sterling Biotech Limited to September 30, 2026. This is a further delay from the previous target of June 30, 2026. According to the company, the extension was mutually agreed upon as the seller is still in the process of fulfilling certain conditions precedent required under the Business Transfer Agreement (BTA).
Separately, Zydus Lifesciences recently received a warning letter from the U.S. Food and Drug Administration (USFDA) regarding its formulation manufacturing facility in Baddi, Himachal Pradesh. The company has clarified that this warning is based on a review of records and not the result of an on-site facility inspection.
The Acquisition Delay
The acquisition of the Sterling Biotech API business has faced multiple timeline adjustments since it was first announced. Initially, the transaction was expected to conclude by December 31, 2024. The latest extension to September 30, 2026, marks the second major delay, indicating that the procedural and regulatory requirements—the conditions precedent—are taking longer than initially anticipated.
For investors, these delays are important because the API business is a key part of Zydus’s vertical integration strategy. While the delay provides short-term cash flow flexibility by deferring the payout, it also pushes back the timeline for realizing potential synergies and capacity additions from the Sterling Biotech assets. The company remains committed to the acquisition, but the repeated extensions highlight the complexities involved in integrating these assets.
The USFDA Warning Letter
The warning letter received in June 2026 stems from a request for records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act. The U.S. regulator raised technical observations regarding the use of purified talc, which did not meet the required United States Pharmacopeia (USP) standards.
It is important for investors to note the distinction the company has made: this warning letter is record-based and not related to an on-site inspection. The Baddi facility was last physically inspected by the USFDA in August 2025, after which it received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification in October 2025. Zydus has maintained that this warning letter will not impact current operations, product supply, or the status of existing approvals from this site.
What Investors Should Track Next
Investors should monitor the company’s updates on the fulfillment of conditions precedent for the Sterling Biotech deal. The next key event will be whether the acquisition is successfully closed by the new September 30, 2026 deadline.
Regarding the USFDA warning, the monitorable will be the company’s remediation response and the USFDA's acceptance of those measures. The company is required to respond to the agency within stipulated timelines, and any further communication from the regulator regarding this site’s compliance status will be a critical factor for the stock.